Litigation Details for City of Providence, Rhode Island v. AbbVie Inc. (S.D.N.Y. 2020)

City of Providence, Rhode Island v. AbbVie Inc. (S.D.N.Y. 2020)

Docket		Date Filed	2020-07-17
Court	District Court, S.D. New York	Date Terminated	2023-08-18
Cause	15:1 Antitrust Litigation (Monopolizing Trade)	Assigned To	Lewis Jeffrey Liman
Jury Demand	Plaintiff	Referred To
Patents	6,545,040
Link to Docket	External link to docket

Details for City of Providence, Rhode Island v. AbbVie Inc. (S.D.N.Y. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2020-07-17	1	Complaint	them of allegedly infringing U.S. Patent No. 6,545,040 (the “’040 Patent”), which Forest successfully submitted…other patent that Forest contended covered Bystolic, U.S. Patent No. 5,759,580 (the “’580 Patent”), or…name.” The ’362 Patent was prior art to the ’040 Patent. In light of the ’362 Patent’s essentially explicit… Forest’s patent settlement agreements with the Generic Competitors in the Bystolic patent litigation…the ’040 Patent, Bystolic would have no generic competitors and Forest would maintain patent-generated	External link to document
2020-10-13	30	Memorandum & Opinion	sued them for infringement of U.S. Patent No. 6,545,040 (the “‘040 patent”). Id. ¶ 5. Each generic company…companies’ position in the patent litigation was very strong. Id. ¶ 7. An earlier patent had disclosed a nebivolol…their products did not infringe the ‘040 patent, or the ‘040 patent was invalid. Nonetheless, between…In June 2015, the last patent protecting Bystolic (other than the ‘040 patent) expired. Id. ¶ 7. It is…that its generic would not infringe the asserted patent claims or the claims were invalid. The	External link to document